A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
Clinical trial NCT06959537 · RECRUITING
Trial details
- NCT number
- NCT06959537
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-13
- Primary completion
- 2027-01-31
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.